Cormorant Asset Management, LP Stoke Therapeutics, Inc. Transaction History
Cormorant Asset Management, LP
- $992 Million
- Q2 2025
A detailed history of Cormorant Asset Management, LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 254,161 shares of STOK stock, worth $5.46 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
254,161
Previous 254,161
-0.0%
Holding current value
$5.46 Million
Previous $1.69 Million
70.65%
% of portfolio
0.29%
Previous 0.18%
Shares
12 transactions
Others Institutions Holding STOK
# of Institutions
148Shares Held
57.2MCall Options Held
2.7KPut Options Held
57.4K-
Black Rock Inc. New York, NY5.41MShares$116 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$116 Million18.16% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$110 Million0.89% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$99.6 Million0.53% of portfolio
-
Redmile Group, LLC San Francisco, CA4.38MShares$94.1 Million6.04% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $848M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...